47 patients with histologically proven Kaposi’s sarcoma were treated with multiple courses of Rezoxane (each course: 1 g/m2/day for 3 days) orally. The overall response was 57% with 20% achieving complete response. The median remission duration of the complete responders is 12 months (range 2–26) with 6 still having sustained complete remissions. Most of the responders were patients with nodular mixed type of Kaposi’s sarcoma. The toxicity was minimal and was mainly leukopenia, alopecia and gastrointestinal disturbance. Rezoxane is a useful safe drug and easy to administer to patients with Kaposi’s sarcoma.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.